| Literature DB >> 16585029 |
David K Ahern1, Jennifer M Kreslake, Judith M Phalen.
Abstract
BACKGROUND: The field of eHealth holds promise for supporting and enabling health behavior change and the prevention and management of chronic disease.Entities:
Mesh:
Year: 2006 PMID: 16585029 PMCID: PMC1550694 DOI: 10.2196/jmir.8.1.e4
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Areas of emphasis by stakeholder group (✓ means prominently addressed by the majority of interviews within indicated sector; -- means minimally addressed or not at all)*
| Access to technology (health disparities) | ✓ | ✓ | ✓ | ✓ | ||
| Cost-effectiveness | ✓ | ✓ | ✓ | |||
| Process measures | ✓ | ✓ | ✓ | |||
| Outcome measures | ✓ | ✓ | ✓ | |||
| Utility (eHealth quality and value) | ✓ | ✓ | ✓ | |||
| Funding for evaluation (obstacle to evaluation) | ✓ | ✓ | ||||
| Market pressures (eHealth quality and value) | ✓ | ✓ | ||||
| Infrastructure | ✓ | ✓ | ||||
| Utilization rates and patterns | ✓ | ✓ | ||||
| Credibility among opinion leaders | ✓ | ✓ | ||||
| Funding for dissemination (obstacle to dissemination) | ✓ | ✓ | ||||
| Reimbursement incentives | ✓ | ✓ | ||||
| Translation from research to practice | -- | -- | -- | -- | -- | |
| Patient-provider tension | -- | -- | -- | -- | -- | |
| Privacy concerns | -- | -- | -- | -- | ||
| Reliability (evaluation approaches) | -- | -- | -- | -- | ||
| Generalizability | -- | -- | -- | |||
| Credibility among providers | -- | -- | -- | |||
| Liability | -- | -- | -- | |||
| Consistency of care | -- | -- | -- | |||
| Combined with standard care | -- | -- | -- |
*Data collectors, purchasers, pharmaceuticals, and consumer group representatives excluded because of small sample size (≤ 2 interviews)
Methodological concerns in eHealth evaluation
| Recruiting representative populations of interest is limited by users’ access and technological literacy. | |
| Controlling for unknown confounders (baseline severity of condition, comorbidity) is especially difficult when evaluating discrete eHealth interventions; quasi-experimental designs, case-control studies, and field trials may not accurately measure impact. | |
| Health care and technology are in a constant state of rapid change, which may change participants’ experiences during the course of a trial or evaluation. | |
| If a large proportion of participants in the intervention group stop using the application, statistical power is reduced and results are biased toward the null. Differential attrition can occur across condition or across level of technological proficiency. | |
| As eHealth programs become more ubiquitous, it will be challenging to find an unexposed control population. |